What would a population-level approach to dementia risk reduction look like, and how would it work?
- PMID: 36791256
- DOI: 10.1002/alz.12985
What would a population-level approach to dementia risk reduction look like, and how would it work?
Abstract
Dementia is a leading global public health challenge. Prevention approaches have traditionally focused on individual-level strategies. However, such approaches have limited potential, particularly for resource-constrained populations in which exposure to risk factors is greatest, and exposure to protective factors is lowest. A population-level approach to dementia risk reduction is therefore essential to meet the scale of the challenge and to tackle global inequalities in risk and incidence of disease. Such approaches can be highly cost effective. In this viewpoint article, we describe what such an approach should look like, barriers and facilitators to success, and how we should go about achieving it. We include 10 strategic goals to achieve population-level dementia risk reduction and protection enhancement, targeted at researchers, professionals, funders, science communicators, governments, businesses, and policy makers. If we are to significantly reduce the prevalence of dementia there must be increased emphasis on population-level approaches. HIGHLIGHTS: Dementia risk reduction is a global public health priority Population-level approaches change societal conditions to make them less conducive to dementia's modifiable risk factors, and increase exposure to protective factors. Urgent development of population-level approaches is required to reduce the prevalence of, and inequalities in, dementia Action is required from researchers, governments and business, funders, public health professionals, and science communicators.
Keywords: dementia; public health; risk reduction.
© 2023 The Authors. Alzheimer's & Dementia published by Wiley Periodicals LLC on behalf of Alzheimer's Association.
Comment in
-
A new dementia prevention approach requires new language.Alzheimers Dement. 2023 Aug;19(8):3749. doi: 10.1002/alz.13362. Epub 2023 Jun 28. Alzheimers Dement. 2023. PMID: 37379460 No abstract available.
-
Authors' response to: A new dementia prevention approach requires new language.Alzheimers Dement. 2023 Aug;19(8):3750-3751. doi: 10.1002/alz.13364. Epub 2023 Jun 28. Alzheimers Dement. 2023. PMID: 37379493 No abstract available.
References
REFERENCES
-
- Prince M. World Alzheimer Report 2015: The Global Impact of Dementia | Alzheimer's Disease International. World Alzheimer's Report. 2015.
-
- Walsh S, King E, Brayne C. France removes state funding for dementia drugs. BMJ. 2019;367:l6930. doi: 10.1136/bmj.l6930
-
- Loy C, Schneider L. Galantamine for Alzheimer's disease and mild cognitive impairment. Cochrane Database Syst Rev. 2006;2006(1):CD001747. doi: 10.1002/14651858.CD001747.pub3
-
- Birks JS, Chong LY, Grimley Evans J. Rivastigmine for Alzheimer's disease. Cochrane Database Syst Rev. 2015(9):CD001191. doi: 10.1002/14651858.CD001191.pub4
-
- Birks JS, Harvey RJ. Donepezil for dementia due to Alzheimer's disease. Cochrane Database Syst Rev. 2018;6(6):CD001190. doi: 10.1002/14651858.CD001190.pub3
MeSH terms
LinkOut - more resources
Full Text Sources
Medical
